Six-Year follow-up clinical study on HOYA Vision Care’s MiYOSMART Spectacle Lens to be presented at ARVO 2022

HOYA Vision Care announced that Professor Carly Lam from the Centre for Myopia Research at The Hong Kong Polytechnic University will present the findings of a six-year follow-up clinical study they conducted on the MiYOSMART spectacle lens with Defocus Incorporated Multiple Segments (D.I.M.S.) Technology to reduce myopia progression in children.

The findings, of the longest running study on a myopia management spectacle lens, will be shared during the Association for Research in Vision and Ophthalmology (ARVO) 2022 conference to be held from May 1-4 in Denver, Colorado, USA.
The presentation will include highlights of the six-year clinical study conducted by researchers at the Hong Kong Polytechnic University which looks at the progression of myopia in children who wore the HOYA Vision Care’s MiYOSMART spectacle lens. This information will enhance a previous three-year follow-up study, a continuation of a two-year randomized control trial (RCT), which was published in the British Journal of Ophthalmology and that demonstrated strong evidence of the lenses’ effectiveness in slowing down the progression of myopia in children ages 8-13.

“This six-year clinical study on the MiYOSMART lens is the longest running study conducted on a myopia management spectacle lens ever, a fact we are very proud of,” said Natalia Vlasak, Ophthalmologist, Global head of Medical and Scientific Affairs at HOYA Vision Care. “Long-term clinical data is essential for evaluating the effectiveness and safety as well as determining possible long-term risks of treatments that can’t be observed during a short period.”

The award winning MiYOSMART lens won the coveted Grand Prize, Grand Award and Gold Medal at the 46th International Exhibition of Inventions of Geneva in April 2018. In October 2020, the spectacle lens won the Silmo d’Or Award in the Vision Category at the Silmo Paris Optical show.

Similar Posts